Farnesoid X Receptor (FXR; NR1H4)
|Product Family||Product Number||Product Description||Technical Manual|
|IB00601-32||Human FXR Reporter Assay System, 3 x 32 assays in 96-well format||Technical Manual|
|IB00601||Human FXR Reporter Assay System, 1 x 96-well format assays||Technical Manual|
|IB00602||Human FXR Reporter Assay System, 1 x 384-well format assays||Technical Manual|
Farnesoid X Receptor Assay Kit
This Farnesoid X Receptor (FXR) assay kit is an all-inclusive FXR reporter assay system that includes, in addition to FXR Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.
FXR Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.
INDIGO’s FXR assay kits feature a luciferase detection reagent specially formulated to provide stable light emission between 5 and 90+ minutes after initiating the luciferase reaction. Incorporating a 5-minute reaction-rest period ensures that light emission profiles attain maximal stability, thereby allowing assay plates to be processed in batch. By doing so, the signal output from all sample wells, from one plate to the next, may be directly compared within an experimental set.
Farnesoid X Receptor Assay Kits are offered in different assay formats to accommodate researchers’ needs: 3 x 32, 1 x 96, and 1 x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications.Assay Kit & Platforms
Bulk assay reagents can be custom manufactured to accommodate any scale of HTS. Please inquire.
FXR assay kit also available in: Mouse, Rat, Cyn Monkey, Dog
Farnesoid X Receptor Assay Services
The primary application of INDIGO’s cell-based Farnesoid X Receptor assays are to quantitatively assess the bioactivity of a test compound as an agonist (activator) or antagonist (inhibition of an agonist response) of a given receptor. Service assays include a positive control reference compound and ‘vehicle’ control for every experiment. A formal study report and all data files are provided to the client upon completion of the study. To receive a quote for your proposed study, complete & submit the online “Request a Quote” form, or, contact an INDIGO Customer Service Representative to discuss your desired study parameters.
FXR Service Assays: Human, Mouse, Rat, Cyn Monkey, Dog
Farnesoid X Receptor Background
The farnesoid X receptor (FXR), also known as NR1H4 is a nuclear hormone receptor with activity similar to that seen in other steroid receptors such as estrogen or progesterone receptor, but more similar in form to PPAR, LXR and RXR. Encoded by the NR1H4 gene, FXR is expressed at high levels in the liver and intestine. Chenodeoxycholic acid and other bile acids are natural ligands for FXR.
Like other steroid receptors, when activated, FXR translocates to the cell nucleus, forms a heterodimer with RXR and binds to hormone response elements on DNA (FXEs) to elicit expression or transrepression of gene products. One of the primary functions of FXR activation is the suppression of cholesterol 7 alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis from cholesterol. FXR does not directly bind to the CYP7A1 promoter. Rather, FXR induces expression of small heterodimer partner (SHP) which then functions to inhibit transcription of the CYP7A1 gene. In this way a negative feedback pathway is established in which synthesis of bile acids is inhibited when cellular levels is already high.
INDIGO's FXR Reporter Assay Systems utilize proprietary mammalian cells engineered to express human NR1H4 protein, commonly referred to as FXR.
The principle application of this FXR assay is in the screening of test samples to quantify functional activities, either as agonist or antagonist, that they may exert against the human farnesoid x receptor.